In a first presentation of the BHS-GAM 2022 session dedicated to novel cellular therapies, Dr. Sophie Servais (CHU Liège, Belgium) shared the results of the first Belgian real-world experience of anti-CD19 CAR-T cells in patients with relapsed or refractory large B-cell lymphoma. Next Prof. Dr. Barbara De Moerloose (University Hospital Ghent, Belgium) shared her personal experience with tisagenlecleucel in the treatment of paediatric and young adults with acute lymphoblastic leukaemia (ALL). In a final presentation, Prof. Dr. Daan Dierickx (University Hospital Leuven, Belgium) discussed the potential of redirecting T-cells against the Epstein–Barr virus, mainly in patients with posttransplant lymphoproliferative disease.